Solventum (SOLV) Q3 2026 earnings review
Solventum clears its software switch, but unpaid customer bills climb
Solventum, the medical and dental supplier spun out of 3M, cleared its biggest computer system switch without losing customer orders. Sales from businesses owned a year ago fell 3% as hospitals worked through inventory they bought early last quarter, beating the drop management had planned for. Removing that order shift, underlying sales rose nearly 4% by our math, and chief executive Bryan Hanson nudged the full-year sales and profit targets up.
| Sales from businesses owned a year ago | -2.8% +3.5% excluding early order reversal by our math |
|---|---|
| Profit per share, excluding one-offs | $1.45 -3.6% from a year ago |
| Free cash flow | $97M -$22M a year ago (boosted by tariff refund) |
| Full-year profit per share outlook | Raised $0.10 new range: $7.20 to $7.30 |
⚖️ Verdict: 🟢 Bullish
The story got better because the company finished its software transition and exited 90% of its 3M service contracts a quarter early, removing the main operational risk for the year. One caution: the $97 million of free cash flow relied on a government tariff refund, while unpaid customer bills rose again to $1.4 billion even though quarterly sales dropped.
The question now is whether Solventum can collect those unpaid bills fast enough to hit its full-year cash flow target, and how much profit margin it gives up when it separates its hospital software division. Either fourth-quarter collections jump as 3M exit costs fade, or billing delays leave the company short of the roughly $280 million in fourth-quarter cash flow that its annual plan requires by our math. Next quarter's cash flow statement and the early 2027 Investor Day will settle both points.
🐂 Bull Case
Software Cutover Cleared Without Disrupting Orders
Solventum makes wound dressings, surgical supplies, dental materials, and hospital billing software. Its biggest operational hurdle this year was switching to its own enterprise resource planning (ERP) software — the computer system that tracks orders and inventory — after leaving former parent 3M. Customers stocked up in the second quarter ahead of the switch, which pulled 6.3 percentage points of sales out of the third quarter.
"Solventum delivered third quarter results ahead of our expectations, with every segment contributing, even as we completed our largest ERP cutover," chief executive Bryan Hanson said. Sales from businesses owned a year ago fell 2.8%, beating the 3% to 4% drop management had planned for. Removing the early order shift, underlying sales grew 3.5% by our math, and the healthcare group lifted its full-year sales target.
The medical supplier also finished all ERP switches and exited about 90% of its 3M service agreements one quarter ahead of schedule. What to watch: fourth-quarter underlying sales growth, which by our math must reach about 3.3% to hit the top of the annual plan. Delivering that figure without order shifts will show where steady demand sits.
Cost Savings Lifted Gross Margins Despite Lower Volume
Solventum runs a multi-year cost-cutting program called Transform for the Future to offset inflation, tariffs, and the expense of standing up its own corporate functions. Last quarter, a one-time tariff refund credit accounted for the entire increase in the full-year margin outlook.
This quarter, gross margin excluding one-offs rose 1.3 percentage points from a year ago to 57.1%, as the cost of making products fell 1.2 percentage points of sales. The company credited "portfolio optimization, mix benefits and savings programs, partially offset by inflation and tariffs". However, operating margin excluding one-offs dipped 0.7 percentage points to 19.9% because overhead and sales costs rose 2.1 points of revenue on lower shipping volume.
What to watch: fourth-quarter separation charges in the income statement reconciliation. Those 3M exit costs ran at $157 million this quarter, and management previously said they would start falling in the fourth quarter now that 90% of service agreements have ended.
Wound Care Clearance Advances Portfolio Shift
Since spinning out of 3M, the Minnesota company has reshaped its lineup by selling its water filtration unit and buying Acera Surgical, a maker of synthetic tissue used to heal complex wounds. Management wants new clinical products to lift growth in MedSurg, its largest division.
During the third quarter, U.S. regulators cleared the combined use of Acera's Restrata wound matrix with Solventum's flagship V.A.C. Therapy negative-pressure wound pumps, "bringing together two advanced wound care technologies". Acquisitions added 7.2 percentage points to Advanced Wound Care sales, lifting the division's reported sales by 8.9% to $528 million even while hospital order shifts weighed on the rest of MedSurg.
What to watch: underlying growth in Advanced Wound Care next quarter once Acera passes its December acquisition anniversary. That reading will show whether pairing the two products speeds up hospital adoption.
🐻 Bear Case
Cash Flow Relied on a Tariff Refund While Bills Stayed Unpaid
Free cash flow — the cash left after capital spending — is the measure Solventum missed last year, and its full-year plan of $200 million to $300 million leaves almost all the work for the second half. This quarter, the company generated $97 million in free cash flow, which it said came in "ahead of expectations driven by IEEPA tariff refund".
- Accounts receivable (unpaid customer bills): $1,364 million, up 34% from a year ago and up $54 million from last quarter
- Nine-month free cash flow: minus $32 million, after $247 million of capital spending
- Fourth-quarter free cash flow required by the annual outlook: $232 million to $332 million by our math
Collecting the government tariff refund took a legal risk off the table, but customer collections moved the wrong way. Unpaid bills grew in the second quarter when customers ordered early, so they should have dropped in the third quarter when sales fell 12% from the prior three months. Instead, receivables rose again. What to watch: fourth-quarter accounts receivable and cash flow, which will show whether the new ERP billing system delayed customer payments.
Software Separation Drags On With No Deal Terms
In August, Solventum announced plans to separate Health Information Systems (HIS), its hospital coding and documentation software division, to focus on medical and dental hardware. "With separation now more than 90% complete and our growth drivers gaining momentum, we are well positioned to accelerate sales growth and expand margins," Hanson said.
The numbers show why giving up the software division complicates that margin goal. HIS was the only division that grew underlying sales this quarter, rising 4.4% to $356 million, and its operating margin expanded 2.9 percentage points to 41.7% — more than double MedSurg's 16.0% and Dental's 20.1%. Meanwhile, Solventum booked another $16 million in acquisition and divestiture advisory expenses, yet gave no update on whether it will sell or spin off the unit.
What to watch: the post-HIS financial targets at the Investor Day planned for the first quarter of 2027. Those figures will show how much profit margin the remaining hardware business loses when software leaves.
Risks this quarter didn't answer
Four standing concerns from prior quarters received no new details in the third-quarter earnings release.
- Clinician productivity software decline: the release did not state whether physician dictation software inside HIS kept shrinking; the quarterly filing's segment section will show the direction.
- Automated coding adoption: management gave no revenue share for its artificial-intelligence coding tools ahead of the planned software separation.
- Bair Hugger lawsuits: Solventum booked $7 million in legal charges this quarter ($178 million over nine months), and the quarterly filing's legal footnote will update the lawsuit count and reserve balance.
- 2027 raw-material cost step-up: the release did not mention negotiations with 3M over a contract clause that could raise supply costs by up to 1 percentage point of margin next year.
💲 Other KPIs
Share buybacks slowed sharply after a heavy second quarter. Solventum spent $48 million buying back stock in the third quarter by our math, down from $288 million in the prior three months, bringing nine-month repurchases to $403 million. Even with the slower pace, the share count used to calculate profit per share excluding one-offs fell about 2.1% from a year ago.
Unearned revenue — cash collected up front on one-year software contracts for service not yet delivered — held steady at $596 million compared with June, and sits 3.5% above the $576 million recorded a year ago. Because these contracts renew annually, the steady balance indicates stable customer renewals in the Health Information Systems division.
Net debt — total borrowings and finance leases of $5,274 million minus $451 million of cash — ticked up by $123 million from June as cash went toward separation expenses and stock buybacks. Following last year's debt paydown from the filtration sale, quarterly net interest expense fell to $68 million from $89 million a year ago.
🔮 Guidance
Raised. Solventum now expects underlying sales growth near the top of its 2.5% to 3.0% range (or 3.5% to 4.0% excluding the 1 percentage point drag from discontinued products). After growing 2.9% over the first nine months, hitting 3.0% for the year leaves about 3.3% growth for the fourth quarter by our math, as ordering normalizes after the third-quarter software switch.
Raised. The middle of the profit target moved up 10 cents to $7.25 per share, representing 18.7% growth over last year's $6.11. This is the third raise this year following moves of +$0.05 and +$0.60. With $5.48 earned in the first nine months, the outlook implies $1.77 per share for the fourth quarter by our math, up 12.7% from $1.57 a year ago.
Unchanged. The medical group kept its full-year cash target at $200 million to $300 million even after collecting the tariff refund in the third quarter. Because free cash flow is minus $32 million through September, hitting the middle of the annual range requires $282 million of cash generation in the fourth quarter alone by our math, compared with $33 million in last year's fourth quarter.
❓ Key Questions
Why did unpaid customer bills rise when sales fell?
Accounts receivable climbed $54 million from June to $1,364 million even though quarterly sales dropped $260 million as early orders reversed. Did the new ERP computer system delay billing or customer collections?
How much did the tariff refund add to Q3 cash?
Solventum said third-quarter free cash flow of $97 million beat expectations because of the IEEPA tariff refund, but did not give the dollar amount collected or say what cash flow was without it.
Is physician dictation software still shrinking inside HIS?
Hospital software grew 4.4% overall, yet management has flagged declines in clinician productivity tools for three straight quarters without disclosing the unit's size or rate of decline.
Will Solventum sell or spin off the software division?
Health Information Systems generates a 41.7% operating margin — double the rest of the company. Without a chosen structure or a stranded-cost estimate, investors cannot calculate the profit drop from separating it.